Clinical trials: Impairment
Hepatic Insufficiency
A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment
The purpose of this study is to measure how much of the drug gets into the bloodstream and how long it takes the body to remove it when given to participants with hepatic (liver) impairment compared to participants with normal…
- Trial name
- NCT01836185
- Testing
- Evacetrapib
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Rimonabant in Abdominally Obese Patients With Impaired Fasting Blood Glucose
Primary objective: To determine the effect of Rimonabant 20mg on the co-primary endpoint including Fasting Plasma Glucose (FPG), HDL-Cholesterol (HDL-C) and triglyceride (TG) levels over a period of 12 months when prescribed with…
- Trial name
- PRADO (NCT00405808)
- Testing
- Rimonabant
- Where
- 27 sites in Austria, Belgium and 25 more
- Volunteers
- 2,666 people
- Sponsor
- Sanofi
Renal Insufficiency
A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment
Multi-center, open-label, single-dose study to assess the PK of a single oral dose of 3 mg CC-122 in subjects with mild, moderate, and severe renal impairment as compared to sex, age (± 15 years), and weight (± 20%) matched…
- Trial name
- NCT03097016
- Testing
- CC-122
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Celgene
Mild Cognitive Impairment (MCI)
To Evaluate the Safety and Efficacy of RP902 Tablets
The purpose of the study is to evaluate the preliminary efficacy of RP902 Tablets in participants with Alzheimer's disease (AD)-derived mild cognitive impairment (MCI) and provide a design basis for the Phase III study.
- Trial name
- NCT07579884
- Testing
- RP902
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- Risen (Suzhou) Pharma Tech Co., Ltd.
Pharmacokinetics of Vepoloxamer, Healthy Volunteers
Study of the Effect of Renal Impairment on the Pharmacokinetics of Vepoloxamer
This is an open-label study designed to evaluate the effect of renal disease on the pharmacokinetics of vepoloxamer relative to the pharmacokinetics in healthy subjects with normal renal function.
- Conditions
- Pharmacokinetics of Vepoloxamer, Healthy Volunteers, Renal Impaired
- Trial name
- NCT02646358
- Testing
- Vepoloxamer
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Mast Therapeutics, Inc.
Walking Impairment, Multiple Sclerosis
Safety and Efficacy of ADS-5102 in Patients With Multiple Sclerosis and Walking Impairment
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed once daily at bedtime for the…
- Trial name
- NCT02471222
- Testing
- ADS-5102
- Where
- 15 sites in United States
- Volunteers
- 60 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Hepatic Impairment, Healthy Participants
An Investigational Study of SHR6390 in Participants With Mild to Moderate Liver Impairment and Healthy Participants
The purpose of this study is to investigate SHR6390 in participants with different levels of liver function
- Trial name
- NCT04631575
- Testing
- SHR6390
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Fatigue, Neoplasms
D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients
To evaluate the efficacy of dexmethylphenidate (d-MPH) in the treatment of chemotherapy-related fatigue in adult cancer subjects.
- Trial name
- NCT00047476
- Testing
- dexmethylphenidate(d-mph)
- Where
- 21 sites in United States
- Volunteers
- 160 people
- Sponsor
- Celgene Corporation
Myelofibrosis
To Evaluate the Pharmacokinetics and Safety of TQ05105 Tablet in Hepatic Impairment Subjects
This is an open, open-label, parallel, single-dose, phase I clinical study designed to evaluate the pharmacokinetic (PK) profile of TQ05105 tablet in patients with hepatic impairment after a single dose, and to evaluate the…
- Trial name
- NCT07480824
- Testing
- TQ05105
- Where
- 2 sites in China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Hepatic Impairment
A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects
This is a multicenter, open-label study to assess the PK of a single 200 mg oral dose of CC-90001 in subjects with mild, moderate, and severe hepatic impairment, and in matched healthy control subjects with normal hepatic…
- Trial name
- NCT03742882
- Testing
- CC-90001
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Celgene
Hepatitis C, Kidney Diseases
VX-950-TiDP24-C132: A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics of Telaprevir.
The purpose of this study is to investigate the effect of severe renal impairment or failure on the single-dose pharmacokinetics of telaprevir (TVR).
- Trial name
- NCT00903773
- Testing
- telaprevir
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Tibotec BVBA
Renal Impairment
Pharmacokinetics of VC005 Tablets in Subjects With Renal Impairment and Normal Renal Function
This study is a Phase I, single-dose, open-label trial designed to evaluate the pharmacokinetics and safety of a single oral dose of 25 mg VC005 tablets in participants with renal impairment compared to participants with normal…
- Trial name
- NCT07551570
- Testing
- VC005 Tablets
- Where
- China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Alzheimer Disease, Mild Cognitive Impairment
Quality Improvement PrecivityAD Clinician Survey (QUIP I)
There is an important unmet need for timely, non-invasive, and low-burden evaluation of patients presenting with mild cognitive impairment (MCI) and early dementia.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia, Cognitive Decline
- Trial name
- QUIP I (NCT05477056)
- Testing
- PrecivityAD blood test
- Where
- United States
- Volunteers
- 366 people
- Sponsor
- C2N Diagnostics
Renal Impairment
A Study to Evaluate The Pharmacokinetics Of Crizotinib (PF-02341066) In Subjects With Impaired Renal Function
The present study is being conducted to evaluate whether or not severe renal impairment has an effect on crizotinib Pharmacokinetics.
- Trial name
- NCT01419041
- Testing
- crizotinib
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetes Mellitus
Effects of Linagliptin on Active GLP-1 Concentrations in Subjects With Renal Impairment
This is a bi-centric, prospective, open study comparing the effects of linagliptin on active GLP-1 concentrations in subjects with renal impairment compared to subjects with normal renal function.
- Trial name
- NCT01903070
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 99 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
HIV, HIV Infections
Open-label Safety Study of E/C/F/TAF (Genvoya®) in HIV-1 Positive Patients With Mild to Moderate Renal Impairment
The primary objective of this study is to evaluate the effect of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) fixed-dose combination (FDC) tablet on renal parameters at Week 24 in treatment-naive and…
- Trial name
- NCT01818596
- Testing
- E/C/F/TAF
- Where
- 70 sites in United States, Australia and 7 more
- Volunteers
- 252 people
- Sponsor
- Gilead Sciences
Healthy Volunteer
A Study of Danoprevir in Healthy Volunteers And Patients With Hepatic Impairment
This non-randomized, multi-center, open-label study will evaluate the pharmacokinetics and the safety and tolerability of danoprevir (RO5190591) and ritonavir in healthy volunteers and patients with mild, moderate or severe…
- Trial name
- NCT01185873
- Testing
- danoprevir, ritonavir
- Where
- 5 sites in United States, Czechia and 1 more
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Mild Cognitive Impairment, Sleep
Home Sleep Therapy for Older Adults With MCI
The goal of this clinical trial is to learn about the ability of non-invasive brain stimulation during sleep to enhance people's deep sleep and its potential benefit on memory in people with mild cognitive impairment via home use…
- Conditions
- Mild Cognitive Impairment, Sleep, Transcranial Electrical Stimulation, Machine Learning
- Trial name
- NCT05771844
- Testing
- Transcranial Electrical Stimulation
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Brain Electrophysiology Laboratory Company
Healthy, Hepatic Insufficiency
A Study of LY3502970 in Participants With Impaired and Normal Liver Function
The main purpose of this study is to measure how much of LY3502970 gets into the bloodstream and how long it takes the body to eliminate it in participants with mild, moderate and severe impaired liver function compared to…
- Trial name
- NCT05882032
- Testing
- LY3502970
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Chronic Kidney Disease, Hepatic Impairment
A Study to Learn About How BAY 3283142 Moves Into, Through, and Out of the Body After a Single Dose in Participants With Reduced Liver Function Compared to Participants With Normal Liver Function
Researchers are looking for a better way to treat people who have chronic kidney disease (CKD). CKD is a condition in which the kidneys' ability to work properly gradually decreases over time.
- Trial name
- NCT06402721
- Testing
- BAY3283142
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Bayer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.